Immunovant (IMVT) Competitors $26.63 -1.42 (-5.06%) (As of 11/15/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends IMVT vs. VVNT, UTZ, ADV, CCIV, HYLN, MRNA, SMMT, VTRS, GMAB, and PCVXShould you be buying Immunovant stock or one of its competitors? The main competitors of Immunovant include Vivint Smart Home (VVNT), Utz Brands (UTZ), Advantage Solutions (ADV), Churchill Capital Corp IV (CCIV), Hyliion (HYLN), Moderna (MRNA), Summit Therapeutics (SMMT), Viatris (VTRS), Genmab A/S (GMAB), and Vaxcyte (PCVX). Immunovant vs. Vivint Smart Home Utz Brands Advantage Solutions Churchill Capital Corp IV Hyliion Moderna Summit Therapeutics Viatris Genmab A/S Vaxcyte Vivint Smart Home (NYSE:VVNT) and Immunovant (NASDAQ:IMVT) are both mid-cap retail/wholesale companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, earnings, risk, media sentiment, institutional ownership, profitability, community ranking, analyst recommendations and valuation. Does the media prefer VVNT or IMVT? In the previous week, Immunovant had 5 more articles in the media than Vivint Smart Home. MarketBeat recorded 5 mentions for Immunovant and 0 mentions for Vivint Smart Home. Immunovant's average media sentiment score of 1.14 beat Vivint Smart Home's score of 0.00 indicating that Immunovant is being referred to more favorably in the news media. Company Overall Sentiment Vivint Smart Home Neutral Immunovant Positive Is VVNT or IMVT more profitable? Immunovant has a net margin of 0.00% compared to Vivint Smart Home's net margin of -3.07%. Vivint Smart Home's return on equity of 0.00% beat Immunovant's return on equity.Company Net Margins Return on Equity Return on Assets Vivint Smart Home-3.07% N/A -1.81% Immunovant N/A -56.40%-52.03% Do analysts prefer VVNT or IMVT? Immunovant has a consensus price target of $48.10, suggesting a potential upside of 80.62%. Given Immunovant's stronger consensus rating and higher probable upside, analysts clearly believe Immunovant is more favorable than Vivint Smart Home.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivint Smart Home 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Immunovant 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do institutionals and insiders believe in VVNT or IMVT? 47.1% of Immunovant shares are owned by institutional investors. 8.6% of Vivint Smart Home shares are owned by company insiders. Comparatively, 5.9% of Immunovant shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Which has better valuation and earnings, VVNT or IMVT? Vivint Smart Home has higher revenue and earnings than Immunovant. Vivint Smart Home is trading at a lower price-to-earnings ratio than Immunovant, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVivint Smart Home$1.68B1.53-$51.73M-$0.24-50.00ImmunovantN/AN/A-$259.34M-$2.22-12.00 Which has more risk & volatility, VVNT or IMVT? Vivint Smart Home has a beta of 0.99, suggesting that its share price is 1% less volatile than the S&P 500. Comparatively, Immunovant has a beta of 0.66, suggesting that its share price is 34% less volatile than the S&P 500. Does the MarketBeat Community favor VVNT or IMVT? Immunovant received 80 more outperform votes than Vivint Smart Home when rated by MarketBeat users. Likewise, 78.21% of users gave Immunovant an outperform vote while only 51.85% of users gave Vivint Smart Home an outperform vote. CompanyUnderperformOutperformVivint Smart HomeOutperform Votes4251.85% Underperform Votes3948.15% ImmunovantOutperform Votes12278.21% Underperform Votes3421.79% SummaryImmunovant beats Vivint Smart Home on 10 of the 17 factors compared between the two stocks. Ad ReticulateThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There is a little known company that is changing warfare. With the backing of U.S. government contracts, this startup is reshaping the future of the U.S. military.Click here to gain instant access to one of the most exclusive pre-ipo opportunities in the market t Get Immunovant News Delivered to You Automatically Sign up to receive the latest news and ratings for IMVT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart IMVT vs. The Competition Export to ExcelMetricImmunovantBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$3.91B$2.91B$5.06B$8.67BDividend YieldN/A1.79%5.06%4.06%P/E Ratio-12.0040.4398.9217.12Price / SalesN/A217.681,205.7371.29Price / CashN/A178.0140.6936.36Price / Book8.704.096.325.87Net Income-$259.34M-$42.42M$119.47M$225.66M7 Day Performance-13.12%-10.63%-5.11%-1.34%1 Month Performance-8.71%-6.02%-3.21%1.00%1 Year Performance-21.03%26.36%32.41%25.27% Immunovant Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)IMVTImmunovant1.6355 of 5 stars$26.63-5.1%$48.10+80.6%-21.0%$3.91BN/A-12.00120Positive NewsVVNTVivint Smart HomeN/A$12.00flatN/A+0.0%$2.58B$1.68B-50.0011,000High Trading VolumeUTZUtz Brands3.2043 of 5 stars$17.41-0.1%N/A+20.4%$2.45B$1.44B-91.633,654ADVAdvantage Solutions2.6107 of 5 stars$3.30-10.6%N/A+25.5%$1.06B$4.22B-8.0570,000CCIVChurchill Capital Corp IVN/A$2.21-0.5%N/A-53.0%$571.84MN/A0.00147,000Gap UpHigh Trading VolumeHYLNHyliion0.5665 of 5 stars$2.82flatN/A+296.0%$489.50M$96,000.00-5.87250News CoverageMRNAModerna4.5631 of 5 stars$42.75-8.7%N/A-51.9%$16.43B$6.85B-7.355,600Analyst ForecastOptions VolumeGap DownHigh Trading VolumeSMMTSummit Therapeutics2.1933 of 5 stars$21.77+1.7%N/A+884.4%$16.05B$700,000.00-77.75105Gap UpVTRSViatris1.3727 of 5 stars$13.09+1.0%N/A+39.9%$15.62B$15.05B-17.6938,000Insider SellingGMABGenmab A/S4.426 of 5 stars$23.20+0.5%N/A-35.6%$15.35B$19.84B22.522,204Short Interest ↑High Trading VolumePCVXVaxcyte3.3295 of 5 stars$103.64-2.8%N/A+73.3%$12.92BN/A-22.53160News Coverage Related Companies and Tools Related Companies VVNT Competitors UTZ Competitors ADV Competitors CCIV Competitors HYLN Competitors MRNA Competitors SMMT Competitors VTRS Competitors GMAB Competitors PCVX Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:IMVT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Immunovant, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Immunovant With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free IMVT Stock Alerts